pre-IPO PHARMA

COMPANY OVERVIEW

Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates. We employ unencumbered decision making, follow the data and advance only those programs that meet our stringent development hurdles. Following clinical proof of concept, we establish value creating partnerships with the world’s leading biotechnology and pharmaceutical companies or advance programs through commercialization. We are continuously seeking new opportunities to leverage our model to create a path to value for our partners and patients.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Dermatology
  • Infectious Disease
  • Oncology
  • Rare Diseases

  • WEBSITE

    https://www.bostonpharmaceuticals.com


    CAREER WEBSITE

    https://www.bostonpharmaceuticals.com/careers


    SOCIAL MEDIA


    INVESTORS

    gurnet-point-capital


    PRESS RELEASES


    Jun 21, 2023

    Boston Pharmaceuticals Announces Positive Phase 2a Results from Monthly and Bi-weekly Dosing with Investigational BOS-580 NASH Program at EASL 2023


    May 18, 2023

    Boston Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting New Phase 2 Clinical Data from BOS-580 NASH Program at EASL 2023


    May 10, 2022

    Boston Pharmaceuticals Appoints Dr. Sophie Kornowski as Chair of its Board of Directors and Acting Chief Executive


    Oct 4, 2021

    Boston Pharmaceuticals Doses First Patient in Phase 2a Clinical Trial of BOS-580 for NASH


    Apr 26, 2021

    Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific


    For More Press Releases


    Google Analytics Alternative